267 related articles for article (PubMed ID: 31492983)
1. PLK4: a promising target for cancer therapy.
Zhao Y; Wang X
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2413-2422. PubMed ID: 31492983
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Polo-like Kinase 4 Inhibitors for the Treatment of Cancer: A Mini Patent Review.
Shu Y; Liu Y; Bian S; Xie Z; Liao C
Mini Rev Med Chem; 2023; 23(1):67-79. PubMed ID: 35657046
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of targeting polo-like kinase 4.
Lei Q; Yu Q; Yang N; Xiao Z; Song C; Zhang R; Yang S; Liu Z; Deng H
Eur J Med Chem; 2024 Feb; 265():116115. PubMed ID: 38199166
[TBL] [Abstract][Full Text] [Related]
4. PLK4: a link between centriole biogenesis and cancer.
Maniswami RR; Prashanth S; Karanth AV; Koushik S; Govindaraj H; Mullangi R; Rajagopal S; Jegatheesan SK
Expert Opin Ther Targets; 2018 Jan; 22(1):59-73. PubMed ID: 29171762
[TBL] [Abstract][Full Text] [Related]
5. Polo-like kinase 4 kinase activity limits centrosome overduplication by autoregulating its own stability.
Holland AJ; Lan W; Niessen S; Hoover H; Cleveland DW
J Cell Biol; 2010 Jan; 188(2):191-8. PubMed ID: 20100909
[TBL] [Abstract][Full Text] [Related]
6. Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers.
Kawakami M; Mustachio LM; Zheng L; Chen Y; Rodriguez-Canales J; Mino B; Kurie JM; Roszik J; Villalobos PA; Thu KL; Silvester J; Cescon DW; Wistuba II; Mak TW; Liu X; Dmitrovsky E
Proc Natl Acad Sci U S A; 2018 Feb; 115(8):1913-1918. PubMed ID: 29434041
[TBL] [Abstract][Full Text] [Related]
7. Chronic centrosome amplification without tumorigenesis.
Vitre B; Holland AJ; Kulukian A; Shoshani O; Hirai M; Wang Y; Maldonado M; Cho T; Boubaker J; Swing DA; Tessarollo L; Evans SM; Fuchs E; Cleveland DW
Proc Natl Acad Sci U S A; 2015 Nov; 112(46):E6321-30. PubMed ID: 26578792
[TBL] [Abstract][Full Text] [Related]
8. YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect.
Lei Q; Xiong L; Xia Y; Feng Z; Gao T; Wei W; Song X; Ye T; Wang N; Peng C; Li Z; Liu Z; Yu L
Cell Death Dis; 2018 Oct; 9(11):1066. PubMed ID: 30337519
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Protein Kinase Inhibitors with PLK4 Cross-Over Potential in a Pre-Clinical Model of Cancer.
Suri A; Bailey AW; Tavares MT; Gunosewoyo H; Dyer CP; Grupenmacher AT; Piper DR; Horton RA; Tomita T; Kozikowski AP; Roy SM; Sredni ST
Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31035676
[TBL] [Abstract][Full Text] [Related]
10. The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.
Sampson PB; Liu Y; Patel NK; Feher M; Forrest B; Li SW; Edwards L; Laufer R; Lang Y; Ban F; Awrey DE; Mao G; Plotnikova O; Leung G; Hodgson R; Mason JM; Wei X; Kiarash R; Green E; Qiu W; Chirgadze NY; Mak TW; Pan G; Pauls HW
J Med Chem; 2015 Jan; 58(1):130-46. PubMed ID: 24867403
[TBL] [Abstract][Full Text] [Related]
11. YLZ-F5, a novel polo-like kinase 4 inhibitor, inhibits human ovarian cancer cell growth by inducing apoptosis and mitotic defects.
Zhu Y; Liu Z; Qu Y; Zeng J; Yang M; Li X; Wang Z; Su J; Wang X; Yu L; Wang Y
Cancer Chemother Pharmacol; 2020 Jul; 86(1):33-43. PubMed ID: 32519033
[TBL] [Abstract][Full Text] [Related]
12. The autoregulated instability of Polo-like kinase 4 limits centrosome duplication to once per cell cycle.
Holland AJ; Fachinetti D; Zhu Q; Bauer M; Verma IM; Nigg EA; Cleveland DW
Genes Dev; 2012 Dec; 26(24):2684-9. PubMed ID: 23249732
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Polo-like kinase 4 induces mitotic defects and DNA damage in diffuse large B-cell lymphoma.
Zhao Y; Yang J; Liu J; Cai Y; Han Y; Hu S; Ren S; Zhou X; Wang X
Cell Death Dis; 2021 Jun; 12(7):640. PubMed ID: 34162828
[TBL] [Abstract][Full Text] [Related]
14. Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts.
Lohse I; Mason J; Cao PM; Pintilie M; Bray M; Hedley DW
Oncotarget; 2017 Jan; 8(2):3064-3071. PubMed ID: 27902970
[TBL] [Abstract][Full Text] [Related]
15. Non-mitotic functions of polo-like kinases in cancer cells.
Raab CA; Raab M; Becker S; Strebhardt K
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188467. PubMed ID: 33171265
[TBL] [Abstract][Full Text] [Related]
16. Functional relationship among PLK2, PLK4 and ROCK2 to induce centrosome amplification.
Ling H; Hanashiro K; Luong TH; Benavides L; Fukasawa K
Cell Cycle; 2015; 14(4):544-53. PubMed ID: 25590559
[TBL] [Abstract][Full Text] [Related]
17. Transient PLK4 overexpression accelerates tumorigenesis in p53-deficient epidermis.
Serçin Ö; Larsimont JC; Karambelas AE; Marthiens V; Moers V; Boeckx B; Le Mercier M; Lambrechts D; Basto R; Blanpain C
Nat Cell Biol; 2016 Jan; 18(1):100-10. PubMed ID: 26595384
[TBL] [Abstract][Full Text] [Related]
18. TRIM37 controls cancer-specific vulnerability to PLK4 inhibition.
Meitinger F; Ohta M; Lee KY; Watanabe S; Davis RL; Anzola JV; Kabeche R; Jenkins DA; Shiau AK; Desai A; Oegema K
Nature; 2020 Sep; 585(7825):440-446. PubMed ID: 32908304
[TBL] [Abstract][Full Text] [Related]
19. Over-expression of Plk4 induces centrosome amplification, loss of primary cilia and associated tissue hyperplasia in the mouse.
Coelho PA; Bury L; Shahbazi MN; Liakath-Ali K; Tate PH; Wormald S; Hindley CJ; Huch M; Archer J; Skarnes WC; Zernicka-Goetz M; Glover DM
Open Biol; 2015 Dec; 5(12):150209. PubMed ID: 26701933
[TBL] [Abstract][Full Text] [Related]
20. Centriole duplication: A lesson in self-control.
Holland AJ; Lan W; Cleveland DW
Cell Cycle; 2010 Jul; 9(14):2731-6. PubMed ID: 20647763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
